Philips showcases latest patient-driven sleep and respiratory solutions at the European Respiratory Society International Congress 2015

September 28, 2015

Highlights include connected sleep solutions and the newest technology for COPD management

Amsterdam, Netherlands – Philips Respironics, a business of Royal Philips (NYSE: PHG, AEX: PHIA), will showcase its latest portfolio of sleep-disordered breathing and respiratory solutions September 26-29 at the European Respiratory Society (ERS) International Congress 2015 in Amsterdam. At booth 1.H_01, Hall 1, clinicians can experience the latest Philips sleep-disordered breathing solutions and new options for COPD management that connect and support the patient, clinician and caregiver to improve patient care and help patients to live active lives.

Sleep: Patient-driven designs for successful OSA treatment
Philips’ sleep therapy portfolio connects the provider and the patient at the most important points in the health continuum, from diagnosis to compliance and ongoing use and resupply. The following new sleep-disordered breathing solutions will be on display during ERS 2015:

  • Dream Family: The new, full integrated, patient-centric sleep therapy solution from Philips featuring a connected positive airway pressure (PAP) therapy device, complementary mask line, and engagement tools to improve care for obstructive sleep apnea (OSA) patients. The Dream Family integrated solution includes the DreamStation PAP device, DreamWear mask, and DreamMapper1 personalized coaching tool. The Dream Family, which will become available to patients and care teams in select countries after October 2015, is designed to engage patients in natural, comfortable and effective sleep therapy while seamlessly connecting them to their care teams for optimal therapy management.
  • Amara View: A minimal contact, full-face mask, the under-the-nose design of Amara View prevents red marks, discomfort and irritation on the bridge of the nose. It also offers the widest field of vision of leading full face masks2.

“As a leader in sleep apnea treatment innovation, Philips continuously aims to expand its CPAP mask offerings with an emphasis on patient comfort,” said Mark D’Angelo, Sleep Business Leader of Philips. “By addressing patient concerns, like limited mobility and mask-related irritation, we can provide patients with more personalized options to help them adapt to and stick with their OSA treatment, and get the sleep they deserve.”

Respiratory: Comprehensive COPD disease state management solutions
Philips Respironics is committed to providing one unified approach to COPD care – coordinated, consistent, uninterrupted and centered around the patient and the home. Our goal is to help reduce hospitalizations, improve patient care, maximize clinician resources and support patients in living more active, fulfilling lives.

Philips will display the following new respiratory solutions at ERS 2015:

  • SimplyGo Mini: With an attractive and sleek design and a comfortable carrying case, SimplyGo Mini is a proven solution for patients who struggle with respiratory disorders to continue living full, active lives. The smallest and lightest portable oxygen concentrator (POC) in the Philips portfolio, SimplyGo Mini delivers nearly 20 percent more oxygen output than any POC weighing five pounds or less3.
  • VitaBreath: VitaBreath is a small, lightweight therapy support device for patients who experience dyspnea related to their COPD4. The portable positive airway pressure (PAP) device provides relief within two minutes and can reduce breathlessness recovery time by up to 40 percent5.

Driving discussion on core sleep and respiratory trends and challenges
Philips executives will participate in the following workshops and symposiums during ERS 2015, providing insight into sleep-disordered breathing and respiratory care:

Practical Workshop: Sunday, September 27, 1:15 – 2:30 p.m. CET, Room E104-106 (E Area)

  • Clinical Usefulness of AVAPS-AE, Nick Hart, BSc PhD MRCP FFICM, Clinical and Academic Director, Lane Fox Respiratory Unit, Guy’s & St Thomas’ NHS Foundation Trust and St Thomas’ Hospital
  • Application of AVAPS-AE to reduce hospital readmissions, Michael Dreher, Global Head of Operations and Customer Service at Philips Healthcare

Evening Symposium: Tuesday, September 29, 5:30 – 7:00 p.m. CET, Room 13.2 (Hall 13)

  • PAP and the Heart: Benefit or Harm
    • Chair: Dr. Teofilo Lee-Chiong, Professor of Medicine, National Jewish Health, Denver
      Speakers: Professor Dr. Winfried J. Randerath, Germany; Douglas Bradley, Canada

Visit Philips Respironics at 1.H_01, Hall 1 during the 2015 ERS International Congress. For more information on Philips’ advanced solutions for sleep and respiratory care and for live updates from ERS 2015, follow @PhilipsLiveFrom and the Philips ERS web site and continue the conversation @PhilipsResp and the Philips Respironics Facebook page.

1 DreamMapper is currently in limited release and being piloted in select markets
2 Data on file, Philips Respironics external and internal testing
3 Data on file, Philips Respironics external and internal testing
4 VitaBreath is currently pending 510(k) approval and is not yet available for sale in the U.S.
5Data on file, Philips Respironics external and internal testing

For further information, please contact:

Alicia Cafardi


About Royal Philips:

Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people's lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2014 sales of EUR 21.4 billion and employs approximately 106,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare. News from Philips is located at


You are about to visit a Philips global content page

You are about to visit the Philips USA website.

Our site can best be viewed with the latest version of Microsoft Edge, Google Chrome or Firefox.